Durable Safety and Efficacy of Voretigene Neparvovec-Rzyl in Postapproval Studies in the USA: CRAning for Perfection.

Luxturna (voretigene neparvovec-rzyl) - Novartis, Roche

Durable Safety and Efficacy of Voretigene Neparvovec-Rzyl in Postapproval Studies in the USA: CRAning for Perfection. (PubMed, Ophthalmology) - Oct 9, 2026 - No abstract available
Journal

http://www.ncbi.nlm.nih.gov/pubmed/42848340

Jean Bennett

Oct 9, 2026